Immune Monitoring and Cancer Omics (IMCO) Laboratories

launched by the Knight Cancer Institute in 2020, were established to provide seamless, comprehensive analytical support for clinical, translational, and basic research studies. IMCO has built an integrated infrastructure of cutting-edge assays and advanced analytics designed to comprehensively characterize immune responses, identify mechanisms of resistance, and develop predictive biomarkers for therapeutic response, risk stratification, and toxicity.

In addition to supporting clinical and translational research, IMCO is deeply committed to advancing basic science. The platform provides researchers with access to state-of-the-art technologies and high-dimensional analytical capabilities to accelerate discovery and enable innovative, hypothesis-driven projects.

IMCO operates as a centralized service laboratory supporting both basic researchers and clinicians. It was developed to consolidate, strengthen, and streamline translational and clinical studies involving human biospecimens. Building upon foundational scientific discoveries and innovative technologies, IMCO delivers scalable, GLP-aligned and CLIA-compliant research assays.